Anthelios Invisible Anti-Shine Mist
Exceptionally high protection sunscreen mist for oily and blemish-prone skin prone to sensitivity.
SPECIFICALLY FORMULATED FOR
Suitable for oily and blemish-prone skin and suitable for skin that is prone to sensitivity, sun-intolerance or prickly-heat. Anthelios’ first very high UVA and UVB protection sunscreen with the light, fresh texture of a thermal spring water. The highly moisturising spray is easy to apply, quickly absorbed and delivers a double anti-shine action with an ultra-dry finish and no residual white marks. A fresh fragrance ensures a long lasting clean skin feeling. Can be worn under or on-top of make-up and can be re-applied throughout the day. Water resistant
- Exceptionally high broad, photostable UVA/UVB & Infrared protection
- Invisible, matt-finish texture
- Can be worn over or under make-up
Enriched with with Airlicium, a cutting-edge ingredient used by NASA, that forms a supple and resistant film over the skin and smoothes its surface whilst letting it breathe. Aircilium absorbs 3 times its weight in oil, keeping the skin matte and unified with a velvet finish.
Anthelios efficacy has been demonstrated via clinical studies carried out in-vivo on subjects suffering from sun intolerances, particularly those caused by UVA rays. Anthelios products all have a high PPD (Persistent Pigment Darkening) factor, offering one of the best protections against UVA offered by any brand in the world. The efficacy has been proven by a file of 16 clinical studies carried out by world-renowned expert dermatologists. The brand was also the first laboratory to use Mexoryl XL and Mexoryl SX and the first to use photostable UVA filters in its sun protection.
9/10 of dermatologists would recommend Anthelios*
MINIMALIST HYPO-ALLERGENIC FORMULA
The minimalist formula contains the best of our creations – designed for sensitive skin and all of its needs. Tested and re-tested for its efficacy and mildness on sensitive skin. It is also hypoallergenic.
This is a cosmetic product. For medical conditions seek advice from your GP
*Survey conducted on 249 dermatologists who chose to attend a La Roche-Posay sponsored symposium in the UK, July 2016